Early Detection and High‐Risk Monitoring of Cell‐Based Genetic Subtypes Using Plasma Biomarkers

Abstract

Background: Genetic subtyping can identify subpopulations at risk for developing Alzheimer Disease (AD), but it cannot detect definitive disease progression. Plasma biomarkers enable a cost‐effective, noninvasive approach to early detection of AD disease.